Roth Capital Expects Aduro Biotech 'To Shine' Next Year After Meeting Management


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Shares of Aduro BioTech Inc (NASDAQ: ADRO) have appreciated 46.14 percent over the past three months, to reach $33.63 on December 16.
  • Roth Capital’s Joseph Pantginis has reiterated a Buy rating on the company, with a price target of $68.
  • While adding the stock to the ROTH Focus List, Pantaginis mentioned the company’s robust cash balance and potential pipeline expansion could help it “shine” in 2016.

According to the Roth Capital report, “With two major partners in hand, a strong cash balance to fund the future of development and potential pipeline expansion we look to Aduro solidifying its place as an immunotherapy leader.”

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Analyst Joseph Pantginis mentioned that Aduro Bio Tech’s “multi-pronged approach” was likely to support opportunities for business development going forward.

Apart from the strong IPO in April 2015, Pantginis believes that the company has made meaningful progress during the year, including “including 1) CRS-207 data for mesothelioma and 2) both Janssen partnered products, ADU-714 and ADU-214 are now in the clinic, both of which were generated from Aduro's LADD platform.”

However, the stock experienced volatility due to the increased weakness in the healthcare sector, as well as “a misguided attempt to drive shares down because of a trial protocol violation needing to be labeled listeriosis,” the report said.

On the other hand, the company has been making strategic moves to become a commercial entity, intending to maintain the U.S. rights for its products, along with potential partnering across its pipeline outside the U.S. as well.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: Analyst ColorLong IdeasReiterationAnalyst RatingsTrading IdeasJoseph PantginisROTH Capital Partners